AIM ImmunoTech (AIM) Total Debt (2011 - 2026)

AIM ImmunoTech's (AIM) quarterly Total Debt came in at $210000.0 in Q1 2026, down 77.35% on a QoQ basis from $927000.0 in Q4 2025.

AIM ImmunoTech (AIM) Total Debt (2011 - 2026) Analysis & Trends

AIM ImmunoTech (AIM) has 11 years of Total Debt data on file, last reported at $210000.0 in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $210000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210000.0 (changed N/A YoY) and the FY2025 annual result came in at $927000.0, changed N/A from the prior year.
Total Debt slipped to $210000.0 in Q1 2026, from $927000.0 in the prior quarter.
In the past five years, Total Debt ranged from a high of $950000.0 in Q1 2024 to a low of $139000.0 in Q3 2024.
A 3-year average of $501800.0 and a median of $283000.0 in 2024 frame the typical range for Total Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.29 Bn	131.44 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	59.49 Bn	54.36 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.02 Bn	36.92 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.79 Bn	27.48 Bn	992.69 Mn	-
7	BioNTech SE	28.26 Bn	9.87 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.30 Bn	26.14 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.10 Bn	26.26 Bn	-	9.34 Bn
10	AIM ImmunoTech	4.36 Mn	-5.60 Mn	21,000.00	-

Download Data